-
If you purchased shares of Dynavax Technologies Corporation (NASDAQ:DVAX), you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
June 17, 2013 (Update) - On June 10, 2013 - Dynavax Technologies Corporation reported that it recently concluded a meeting with the U.S. Food and Drug Administration (FDA) regarding its Biologic License Application for HEPLISAV, an investigational adult hepatitis B vaccine. Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) fell from $2.55 per share on June 6, 2013 to $1.22 per...
You must register (for free) or login to view the entire investigation.
